Lummis Asset Management LP Has $4.16 Million Position in Abbott Laboratories $ABT

Lummis Asset Management LP trimmed its stake in Abbott Laboratories (NYSE:ABT) by 32.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,056 shares of the healthcare product maker’s stock after selling 14,731 shares during the period. Abbott Laboratories makes up about 2.7% of Lummis Asset Management LP’s portfolio, making the stock its 10th biggest position. Lummis Asset Management LP’s holdings in Abbott Laboratories were worth $4,160,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Carr Financial Group Corp boosted its stake in shares of Abbott Laboratories by 2.0% during the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock valued at $520,000 after purchasing an additional 76 shares in the last quarter. Tortoise Investment Management LLC boosted its holdings in Abbott Laboratories by 10.7% in the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock valued at $108,000 after purchasing an additional 77 shares during the last quarter. Gemmer Asset Management LLC grew its position in Abbott Laboratories by 2.9% during the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after purchasing an additional 78 shares during the period. Bridgewater Advisors Inc. raised its position in Abbott Laboratories by 0.6% during the second quarter. Bridgewater Advisors Inc. now owns 12,555 shares of the healthcare product maker’s stock valued at $1,607,000 after acquiring an additional 79 shares in the last quarter. Finally, Global Financial Private Client LLC lifted its stake in shares of Abbott Laboratories by 3.3% in the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock valued at $331,000 after purchasing an additional 79 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Large end‑market tailwinds — multiple industry reports highlight strong long‑term growth for genetic testing, cancer diagnostics and personalized medicine, and name Abbott among market leaders; that supports durable demand for Abbott’s diagnostics and genomics businesses. Genetic Testing Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Sustainability, Launches, Mergers, Product Innovations, Revenue Insights
• Positive Sentiment: Analyst support and price targets remain constructive — several Buy/Overweight ratings recently reiterated and the median 6‑month target sits near $140, providing upside expectations if growth and margins recover. Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition
• Positive Sentiment: Dividend continuity — Abbott declared a $0.63 quarterly dividend (yield ~2.2%), supporting investor income expectations and signaling cash‑return discipline.
• Neutral Sentiment: Q4 results were mixed: EPS matched consensus ($1.50) but revenue (~$11.46B) trailed estimates; management provided FY‑2026 and Q1 guidance — the print shows stable profitability but moderating top‑line momentum, so near‑term reaction depends on guidance detail and margin trajectory. Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say
• Neutral Sentiment: Exact Sciences acquisition financing — Abbott announced a large bond sale (reported ~$20B) to fund the deal. The acquisition aims to deepen cancer‑screening/diagnostics exposure (strategic upside) but raises leverage and integration risk; investors are divided on whether the move is accretive. Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition
• Negative Sentiment: Legal and safety risk — a wrongful‑death lawsuit alleges defects in Abbott’s FreeStyle Libre 3 glucose monitors, claiming multiple deaths and serious injuries; this poses potential regulatory, litigation and reputational costs if claims advance. Wrongful Death Suit Tests Abbott Libre 3 And Exact Sciences Ambitions

Insiders Place Their Bets

In related news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The stock was bought at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the purchase, the director directly owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ABT shares. Citigroup lowered their target price on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Sanford C. Bernstein dropped their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Piper Sandler reduced their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday, January 23rd. Finally, Freedom Capital upgraded shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Stock Down 0.6%

Shares of Abbott Laboratories stock opened at $114.65 on Wednesday. The company has a quick ratio of 1.24, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23. The company has a market capitalization of $199.23 billion, a P/E ratio of 30.82, a P/E/G ratio of 1.83 and a beta of 0.75. The company has a 50 day moving average of $117.94 and a 200 day moving average of $125.55.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same period last year, the firm earned $1.34 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.